SMS Lifesciences India Limited (SMSLIFE.BO)
INR 1176.0
(0.0%)
INR 1176.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 329.57 Million INR | -61.02% |
| 2022 | 845.45 Million INR | -3.42% |
| 2021 | 875.42 Million INR | 24.68% |
| 2020 | 702.12 Million INR | 20.13% |
| 2019 | 584.47 Million INR | -12.5% |
| 2018 | 667.99 Million INR | 83.55% |
| 2017 | 363.92 Million INR | -27.54% |
| 2016 | 502.26 Million INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 148.37 Million INR | 11.09% |
| 2023 Q3 | 259.34 Million INR | 7.79% |
| 2023 FY | 329.57 Million INR | -61.02% |
| 2023 Q2 | 240.6 Million INR | 39.14% |
| 2023 Q1 | 172.92 Million INR | 11.66% |
| 2023 Q4 | 133.56 Million INR | -48.5% |
| 2022 Q2 | 218.58 Million INR | -2.44% |
| 2022 Q3 | 247.96 Million INR | 13.44% |
| 2022 Q4 | 154.86 Million INR | -37.55% |
| 2022 Q1 | 224.04 Million INR | 14.59% |
| 2022 FY | 845.45 Million INR | -3.42% |
| 2021 Q4 | 195.51 Million INR | -16.88% |
| 2021 FY | 875.42 Million INR | 24.68% |
| 2021 Q2 | 241.02 Million INR | 18.34% |
| 2021 Q1 | 203.66 Million INR | 20.03% |
| 2021 Q3 | 235.22 Million INR | -2.41% |
| 2020 Q2 | 198.51 Million INR | 24.97% |
| 2020 FY | 702.12 Million INR | 20.13% |
| 2020 Q1 | 158.84 Million INR | 65.02% |
| 2020 Q3 | 175.1 Million INR | -11.79% |
| 2020 Q4 | 169.67 Million INR | -3.1% |
| 2019 Q2 | 188.34 Million INR | -0.38% |
| 2019 FY | 584.47 Million INR | -12.5% |
| 2019 Q4 | 96.25 Million INR | -12.85% |
| 2019 Q3 | 110.45 Million INR | -41.36% |
| 2019 Q1 | 189.05 Million INR | 15.02% |
| 2018 Q1 | 146.1 Million INR | 50.19% |
| 2018 FY | 667.99 Million INR | 83.55% |
| 2018 Q4 | 164.36 Million INR | -24.34% |
| 2018 Q3 | 217.25 Million INR | 37.37% |
| 2018 Q2 | 158.15 Million INR | 8.25% |
| 2017 Q3 | 117.76 Million INR | 29.29% |
| 2017 Q4 | 97.27 Million INR | -17.4% |
| 2017 FY | 363.92 Million INR | -27.54% |
| 2017 Q1 | 99.16 Million INR | -28.68% |
| 2017 Q2 | 91.08 Million INR | -8.15% |
| 2016 Q1 | 277.04 Million INR | 0.0% |
| 2016 Q3 | 301.4 Million INR | 30.44% |
| 2016 Q2 | 231.06 Million INR | -16.6% |
| 2016 FY | 502.26 Million INR | 0.0% |
| 2016 Q4 | 139.04 Million INR | -53.87% |
| 2015 FY | - INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 10.46 Million INR | -3050.521% |
| Biocon Limited | 91.73 Billion INR | 99.641% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | 89.568% |
| Concord Biotech Limited | 6.11 Billion INR | 94.607% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | 93.279% |
| FERMENTA BIOTECH LIMITED | 1.82 Billion INR | 81.913% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | -19865.228% |
| Lyka Labs Limited | 145.95 Million INR | -125.811% |
| Panacea Biotec Limited | 1.35 Billion INR | 75.682% |
| SAMSRITA LABS LIMITED | -1.28 Million INR | 25786.517% |
| Servoteach Industries Limited | - INR | -Infinity% |
| Supriya Lifescience Limited | 2.65 Billion INR | 87.572% |
| Syngene International Limited | 12.43 Billion INR | 97.35% |
| TAKE Solutions Limited | 183.42 Million INR | -79.684% |
| Titan Biotech Limited | 884.66 Million INR | 62.745% |
| Transgene Biotek Limited | -1.69 Million INR | 19578.487% |
| Vanta Bioscience Limited | 7.12 Million INR | -4528.876% |